Tranexamic acid is an antifibrinolytic used to control bleeding during hemorrhages, such as postpartum hemorrhages, according to a news release shared with Becker’s.
The inclusion to the 2024 high-alert list, which began with six drugs in 1989, is based on expert consensus.
Safety experts said “errors involving tranexamic acid for injection are frequently related to storage issues and mix-ups with look-alike medication vials, most often anesthetics that are also commonly stored in surgical and procedural locations. When accidentally administered via a neuraxial route, tranexamic acid injection is a potent neurotoxin with a mortality rate of about 50%, and almost always harmful to the patient.”
The list can be accessed here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.